- Home
- AEYE vs FENC Comparison
AEYE vs FENC Comparison
Compare AEYE & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEYE
- FENC
- Stock Information
- Founded
- AEYE 2005
- FENC 1996
- Country
- AEYE United States
- FENC United States
- Employees
- AEYE N/A
- FENC N/A
- Industry
- AEYE Computer Software: Prepackaged Software
- FENC Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AEYE Technology
- FENC Health Care
- Exchange
- AEYE Nasdaq
- FENC Nasdaq
- Market Cap
- AEYE 138.0M
- FENC 156.9M
- IPO Year
- AEYE N/A
- FENC 2001
- Fundamental
- Price
- AEYE $12.46
- FENC $5.95
- Analyst Decision
- AEYE Strong Buy
- FENC Strong Buy
- Analyst Count
- AEYE 5
- FENC 2
- Target Price
- AEYE $26.40
- FENC $14.00
- AVG Volume (30 Days)
- AEYE 117.6K
- FENC 50.4K
- Earning Date
- AEYE 04-29-2025
- FENC 05-20-2025
- Dividend Yield
- AEYE N/A
- FENC N/A
- EPS Growth
- AEYE N/A
- FENC N/A
- EPS
- AEYE N/A
- FENC N/A
- Revenue
- AEYE $36,851,000.00
- FENC $47,538,000.00
- Revenue This Year
- AEYE $20.29
- FENC $2.68
- Revenue Next Year
- AEYE $18.65
- FENC $71.63
- P/E Ratio
- AEYE N/A
- FENC N/A
- Revenue Growth
- AEYE 16.52
- FENC 123.69
- 52 Week Low
- AEYE $8.91
- FENC $3.96
- 52 Week High
- AEYE $34.85
- FENC $10.07
- Technical
- Relative Strength Index (RSI)
- AEYE 56.11
- FENC 51.33
- Support Level
- AEYE $11.17
- FENC $5.85
- Resistance Level
- AEYE $12.60
- FENC $6.61
- Average True Range (ATR)
- AEYE 1.05
- FENC 0.36
- MACD
- AEYE 0.12
- FENC 0.06
- Stochastic Oscillator
- AEYE 91.08
- FENC 54.20
About AEYE AudioEye Inc.
AudioEye Inc is a software solution provider delivering immediate ADA and WCAG accessibility compliance at scale. Through patented technology, subject matter expertise and proprietary processes, it is eradicating all barriers to digital accessibility, helping creators get accessible and supporting them with ongoing advisory and automated upkeep. Trusted by the ADP, Tommy Hilfiger, A360 Media, Samsung, Landry's and others. It helps everyone identify and resolve issues of accessibility and enhance user experiences, automating digital accessibility for the widest audiences.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.